Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | WNT3A | P56704 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | TSHR | P16473 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | GRM5 | P41594 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22473361 | 0.96 | PRMT5 (0.43) | LMNANPSR1MAPTALDH1A1WNT3A | |
| SCHEMBL29953798 | 0.87 | UCHL1 (0.52) | LMNANPSR1MAPTALDH1A1RIPK1 | |
| SCHEMBL14240400 | 0.87 | ALDH1A1 (0.43) | LMNANPSR1MAPTALDH1A1RIPK1 | |
| SCHEMBL22726599 | 0.87 | UCHL1 (0.52) | LMNANPSR1MAPTALDH1A1RIPK1 | |
| SCHEMBL30745375 | 0.86 | ALDH1A1 (0.45) | LMNANPSR1MAPTALDH1A1RIPK1 | |
| SCHEMBL18394381 | 0.83 | PROKR1 (0.45) | MAPTRIPK1GRM5PROKR1 | |
| SCHEMBL20281685 | 0.81 | PROKR1 (0.56) | ALDH1A1WNT3APROKR1 | |
| SCHEMBL18406191 | 0.81 | LMNA (0.51) | LMNANPSR1MAPTALDH1A1L3MBTL1 | |
| SCHEMBL878861 | 0.80 | NPSR1 (0.56) | LMNANPSR1MAPTALDH1A1RIPK1 | |
| SCHEMBL22473277 | 0.80 | UCHL1 (0.45) | LMNANPSR1ALDH1A1WNT3AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148668-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
| US-10538509-B2 | Decarboxylative cross-coupling and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-01-21 | — | — | US | disclosed |
| US-20170022185-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2017-01-26 | — | — | US | disclosed |
| US-20170022185-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2017-01-26 | — | — | US | disclosed |
| WO-2015153381-A2 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-10-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170022185-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | PPOX, DDO, DDC | LMNA 4743/4885NPSR1 4420/4885MAPT 2906/4885 |
| US-10538509-B2 | Decarboxylative cross-coupling and applications thereof | PPOX, DDC, DDO | LMNA 4676/4885NPSR1 4512/4885MAPT 3004/4885 |
| US-20200148668-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | PPOX, DDO, DDC | LMNA 4743/4885NPSR1 4420/4885MAPT 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.